Drug Profile
Research programme: CNS disorders therapies - Thuris
Latest Information Update: 04 Feb 2011
Price :
$50
*
At a glance
- Originator Thuris Corporation
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 31 Dec 2006 Discontinued - Preclinical for Neurological disorders in USA (PO)
- 30 Jul 2004 This programme is available for licensing(http://www.thuris.com)
- 30 Jul 2004 Preclinical trials in Neurological disorders in USA (PO)